, a bio/informatics shared resource is still "open for business" - Visit the CDS website


W. Rathmell
Last active: 11/27/2019

  1. Physician and stakeholder perceptions of conflict of interest policies in oncology. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK (2013) J Clin Oncol 31(13): 1677-82
    › Primary publication · 23530092 (PubMed) · PMC4525129 (PubMed Central)
  2. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) Cell Metab 17(3): 372-85
    › Primary publication · 23473032 (PubMed) · PMC4003458 (PubMed Central)
  3. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM (2013) Cancer Med 2(4): 545-52
    › Primary publication · 24156027 (PubMed) · PMC3799289 (PubMed Central)
  4. Ethical challenges: managing oncology drug shortages. Valgus J, Singer EA, Berry SR, Rathmell WK (2013) J Oncol Pract 9(2): e21-3
    › Primary publication · 23814521 (PubMed) · PMC3595447 (PubMed Central)
  5. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J (2013) Lancet Oncol 14(2): 159-167
    › Primary publication · 23333114 (PubMed) · PMC4674067 (PubMed Central)
  6. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ (2013) Urol Oncol 31(1): 82-6
    › Primary publication · 21396844 (PubMed)
  7. State of the science: an update on renal cell carcinoma. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK (2012) Mol Cancer Res 10(7): 859-80
    › Primary publication · 22638109 (PubMed) · PMC3399969 (PubMed Central)
  8. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y (2012) Mol Cell 45(2): 233-43
    › Primary publication · 22284679 (PubMed) · PMC3982234 (PubMed Central)
  9. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK (2012) Nucl Med Commun 33(9): 967-73
    › Primary publication · 22714005 (PubMed)
  10. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Khandani AH, Rathmell WK (2012) Semin Nucl Med 42(4): 221-30
    › Primary publication · 22681671 (PubMed)